Oculis Holding Ag (OCS)

$27.48 0.00 (N/A)
Market Cap 1.59B
Revenue (ttm) 1.45M
Net Income (ttm) -119.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -8,237.24%
Debt to Equity Ratio 0.00
Volume 161,000
Avg Vol 363,364
Day's Range N/A - N/A
Shares Out 57.98M
Stochastic %K 48%
Beta 0.48
Analysts Strong Sell
Price Target $47.71

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease m...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 711 3960
Website: oculis.com
Address:
Bahnhofstrasse 20, Zug, Switzerland
justiceforb_85
justiceforb_85 Apr. 28 at 10:31 PM
$OCS look forward to P3 data for OCS-01 in DME.
0 · Reply
DianeChristmas423
DianeChristmas423 Apr. 27 at 7:31 PM
$OCS low liquidity feel, tape changes fast if volume finally shows
0 · Reply
laaarsas
laaarsas Apr. 27 at 11:02 AM
$OCS Seems like market could be pricing this too high
0 · Reply
laaarsas
laaarsas Apr. 25 at 2:03 PM
$OCS I think I lean towards ph3 success but for me there are many factors that are hard to assess here, much is unknown. Might stay outside of this one.
0 · Reply
laaarsas
laaarsas Apr. 25 at 1:31 PM
$OCS One of the hardest questions for me to answer is what effect size the market is expecting. What bar do we need to reach to be considered to have a clear win?
1 · Reply
laaarsas
laaarsas Apr. 25 at 12:19 PM
$OCS I'm not getting this case. Ok eye drops for DME seems interesting. But I see data risk. Confidence intervals are broad. Ph2 data set with worse BCVA... mean for entire ph2 was 64 BCVA. For stage 1 it was 58. Is the difference that big? Does it really explain the results? Or is it at post-hoc signal? I think there is too much incertainty for me dig deeper here... might look somewhere else... I would not be surprised if it works, but also the other way around. The entry does not seem so obvious at face value? What do you think? Seems current data is very varying... I don't know I think this one is a bit hard?
1 · Reply
laaarsas
laaarsas Apr. 25 at 1:52 AM
$OCS I don’t get it. They will never be able to compete with aVEGF efficacy-wise in DME. What’s their niche?
0 · Reply
laaarsas
laaarsas Apr. 24 at 12:54 PM
$OCS What's the case here? Bull and bear?
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 24 at 3:07 AM
$OCS Share Price: $26.70 Contract Selected: Aug 21, 2026 $25 Calls Buy Zone: $4.67 – $5.78 Target Zone: $7.94 – $9.71 Potential Upside: 60% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Champi2305
Champi2305 Apr. 23 at 11:51 AM
$OCS Here there are only 120 watchers but the potential is amazing. https://www.linkedin.com/mwlite/feed/posts/riad-sherif-277376_aan-acuity-privosegtor-ugcPost-7452784371750572032-YJ8G?utm_source=share&utm_medium=member_ios&rcm=ACoAABejjSUBaMqRLwPlXxwgBO-eLPqRJvPW21g
0 · Reply
Latest News on OCS
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 1, 2026, 4:00 AM EDT - 20 hours ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Apr 21, 2026, 4:05 PM EDT - 10 days ago

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Apr 20, 2026, 4:00 AM EDT - 11 days ago

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 9:30 AM EDT - 17 days ago

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Apr 8, 2026, 4:05 PM EDT - 23 days ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis to Participate in Upcoming Investor Conferences

Apr 7, 2026, 4:00 AM EDT - 24 days ago

Oculis to Participate in Upcoming Investor Conferences

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Mar 31, 2026, 5:00 AM EDT - 4 weeks ago

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Mar 16, 2026, 5:00 AM EDT - 6 weeks ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 7 weeks ago

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Oculis Publishes 2025 Consolidated Financial Statements

Mar 5, 2026, 4:00 AM EST - 2 months ago

Oculis Publishes 2025 Consolidated Financial Statements

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Mar 3, 2026, 4:05 PM EST - 2 months ago

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Feb 18, 2026, 4:05 PM EST - 2 months ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Oculis Appoints Katie Kazem as Chief Legal Officer

Feb 17, 2026, 4:00 AM EST - 2 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 3 months ago

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:00 AM EST - 4 months ago

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Jan 6, 2026, 4:00 AM EST - 4 months ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 6 months ago

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 12:30 PM EST - 6 months ago

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Nov 10, 2025, 4:05 PM EST - 6 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Oculis to Participate in Upcoming November Investor Conferences

Nov 5, 2025, 4:00 AM EST - 6 months ago

Oculis to Participate in Upcoming November Investor Conferences

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oct 30, 2025, 4:30 AM EDT - 6 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oct 14, 2025, 4:00 AM EDT - 7 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oculis Holding AG Transcript: Status Update

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Oculis Holding AG Transcript: Status Update

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oct 6, 2025, 4:07 AM EDT - 7 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Sep 26, 2025, 4:05 PM EDT - 7 months ago

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Sep 22, 2025, 4:00 AM EDT - 7 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 3:45 PM EDT - 8 months ago

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:30 PM EDT - 8 months ago

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Sep 4, 2025, 1:00 PM EDT - 8 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Sep 1, 2025, 4:00 AM EDT - 8 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Oculis to Participate in Upcoming September Investor Conferences

Aug 28, 2025, 4:00 AM EDT - 8 months ago

Oculis to Participate in Upcoming September Investor Conferences

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Aug 25, 2025, 4:00 AM EDT - 8 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Aug 21, 2025, 4:05 PM EDT - 9 months ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Oculis Holding AG Transcript: Fireside Chat

Aug 13, 2025, 11:00 AM EDT - 9 months ago

Oculis Holding AG Transcript: Fireside Chat

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 9 months ago

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 9 months ago

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 9 months ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis Upsized Loan Facility to Access up to CHF 100 million

Aug 1, 2025, 4:00 AM EDT - 9 months ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Publishes Results of 2025 Annual General Meeting

Jun 5, 2025, 4:00 AM EDT - 11 months ago

Oculis Publishes Results of 2025 Annual General Meeting

Oculis to Participate in Upcoming June Investor Conferences

Jun 3, 2025, 4:00 AM EDT - 11 months ago

Oculis to Participate in Upcoming June Investor Conferences

Oculis Holding AG Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 1:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: Stifel 2025 Virtual Ophthalmology Forum

Oculis Holding AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Oculis Holding AG Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 6:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: BofA Securities 2025 Healthcare Conference

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q1 2025 Financial Results and Provides Company Update

Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q1 Financial Results and Provides Company Update

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis Updates Share Capital

Apr 25, 2025, 4:00 PM EDT - 1 year ago

Oculis Updates Share Capital

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Apr 17, 2025, 5:00 AM EDT - 1 year ago

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Oculis Holding AG Transcript: R&D Day 2025

Apr 15, 2025, 10:00 AM EDT - 1 year ago

Oculis Holding AG Transcript: R&D Day 2025

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Apr 15, 2025, 4:00 AM EDT - 1 year ago

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 4:00 AM EDT - 1 year ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Apr 1, 2025, 4:00 AM EDT - 1 year ago

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Mar 20, 2025, 6:01 PM EDT - 1 year ago

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Oculis Holding AG Transcript: Leerink's Global Healthcare Conference 2025

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: Leerink's Global Healthcare Conference 2025

Oculis to Present at Upcoming March Investor Conference

Mar 5, 2025, 4:00 AM EST - 1 year ago

Oculis to Present at Upcoming March Investor Conference

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Feb 13, 2025, 7:40 PM EST - 1 year ago

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Oculis updates share capital for its existing at-the-market offering program

Jan 31, 2025, 4:00 PM EST - 1 year ago

Oculis updates share capital for its existing at-the-market offering program

Oculis Holding AG Transcript: Study Result

Jan 6, 2025, 8:00 AM EST - 1 year ago

Oculis Holding AG Transcript: Study Result

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Jan 6, 2025, 3:53 AM EST - 1 year ago

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

Nov 27, 2024, 4:15 AM EST - 1 year ago

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

Oculis Holding AG Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 9:10 AM EST - 1 year ago

Oculis Holding AG Transcript: Stifel 2024 Healthcare Conference

Oculis to Present at the Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:00 AM EST - 1 year ago

Oculis to Present at the Stifel 2024 Healthcare Conference

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Nov 7, 2024, 4:00 AM EST - 1 year ago

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis Holding AG Transcript: The Baird 2024 Global Healthcare Conference

Sep 11, 2024, 12:45 PM EDT - 1 year ago

Oculis Holding AG Transcript: The Baird 2024 Global Healthcare Conference

Oculis Holding AG Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 11, 2024, 9:30 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Oculis Holding AG Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Oculis Holding AG Transcript: Study Result

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Oculis Holding AG Transcript: Study Result

justiceforb_85
justiceforb_85 Apr. 28 at 10:31 PM
$OCS look forward to P3 data for OCS-01 in DME.
0 · Reply
DianeChristmas423
DianeChristmas423 Apr. 27 at 7:31 PM
$OCS low liquidity feel, tape changes fast if volume finally shows
0 · Reply
laaarsas
laaarsas Apr. 27 at 11:02 AM
$OCS Seems like market could be pricing this too high
0 · Reply
laaarsas
laaarsas Apr. 25 at 2:03 PM
$OCS I think I lean towards ph3 success but for me there are many factors that are hard to assess here, much is unknown. Might stay outside of this one.
0 · Reply
laaarsas
laaarsas Apr. 25 at 1:31 PM
$OCS One of the hardest questions for me to answer is what effect size the market is expecting. What bar do we need to reach to be considered to have a clear win?
1 · Reply
laaarsas
laaarsas Apr. 25 at 12:19 PM
$OCS I'm not getting this case. Ok eye drops for DME seems interesting. But I see data risk. Confidence intervals are broad. Ph2 data set with worse BCVA... mean for entire ph2 was 64 BCVA. For stage 1 it was 58. Is the difference that big? Does it really explain the results? Or is it at post-hoc signal? I think there is too much incertainty for me dig deeper here... might look somewhere else... I would not be surprised if it works, but also the other way around. The entry does not seem so obvious at face value? What do you think? Seems current data is very varying... I don't know I think this one is a bit hard?
1 · Reply
laaarsas
laaarsas Apr. 25 at 1:52 AM
$OCS I don’t get it. They will never be able to compete with aVEGF efficacy-wise in DME. What’s their niche?
0 · Reply
laaarsas
laaarsas Apr. 24 at 12:54 PM
$OCS What's the case here? Bull and bear?
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 24 at 3:07 AM
$OCS Share Price: $26.70 Contract Selected: Aug 21, 2026 $25 Calls Buy Zone: $4.67 – $5.78 Target Zone: $7.94 – $9.71 Potential Upside: 60% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Champi2305
Champi2305 Apr. 23 at 11:51 AM
$OCS Here there are only 120 watchers but the potential is amazing. https://www.linkedin.com/mwlite/feed/posts/riad-sherif-277376_aan-acuity-privosegtor-ugcPost-7452784371750572032-YJ8G?utm_source=share&utm_medium=member_ios&rcm=ACoAABejjSUBaMqRLwPlXxwgBO-eLPqRJvPW21g
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 20 at 12:52 PM
$OCS (+1.6% pre) 800+ patients finish Oculis diabetic eye-drop trials before June data https://ooc.bz/l/99281
0 · Reply
briefingcom
briefingcom Apr. 20 at 12:35 PM
$OCS: Oculis Holding AG announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND program in diabetic macular edema; Oculis expects to report topline results in June 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260420061431OCS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Champi2305
Champi2305 Apr. 20 at 10:49 AM
$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-announces-completion-last-patient-visit-phase-3-diamond/
0 · Reply
Champi2305
Champi2305 Apr. 7 at 11:04 AM
$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-participate-upcoming-investor-conferences-1/
0 · Reply
Champi2305
Champi2305 Mar. 31 at 10:26 AM
$OCS Another good news https://www.marketscreener.com/news/oculis-announces-european-medicines-agency-prime-designation-for-privosegtor-advancing-a-potential-ce7e51ded88df722
0 · Reply
Champi2305
Champi2305 Mar. 26 at 11:20 AM
$OCS https://www.linkedin.com/mwlite/feed/posts/oculis-sa_visionaryinnovation-drugdevelopment-ophthalmology-activity-7442163026755010561-51zA?utm_medium=ios_app&rcm=ACoAABMZRdMBlGhO7Tg-zVtf8-4gsA6mldcf0p8&utm_source=social_share_send&utm_campaign=whatsapp
0 · Reply
Champi2305
Champi2305 Mar. 26 at 11:19 AM
$OCS https://pioneer-program.com/patient/
0 · Reply
Doozio
Doozio Mar. 10 at 5:34 PM
$OCS off the 50d as they go MNDY Thursday VIX 🐑 as NIO ♾️ gets da message from da ORCL ♾️ during 🐒🍌🧠⏰♾️? N all yo gotta do is wUtch how NUTX
0 · Reply
Champi2305
Champi2305 Mar. 10 at 4:16 PM
$OCS offering at the highest price.
0 · Reply
Champi2305
Champi2305 Mar. 10 at 3:37 PM
$OCS
0 · Reply
Champi2305
Champi2305 Mar. 10 at 6:22 AM
$OCS OCS-1 is just the beginning of a new age for Oculis and a new age for patients obviously. Licaminlimab Will follow at the end of the year. The age of the potential buyout is possible for shareholders but I think it could happens in the end of 2027 with the results of privogestor when this product will deliver all its potential in multiple sclerosis relapses and after ON and NAION phases 3 results.
0 · Reply